UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of the registrant as specified in its charter)
| |
|
|
|
|
|
ISRAEL
|
|
001-16174
|
|
|
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
| |
|
|
|
5 Basel Street, Petach Tikva, Israel
|
|
4951033
|
|
(Address of principal executive offices)
|
|
(Zip code)
|
Eyal Desheh
Group Executive Vice President, Chief Financial Officer
Tel: 972-3-914-8171
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed and provide the period to which the information in this form applies:
|
☒
|
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2016.
|
Items 1.01 and 1.02 Conflict Minerals Disclosure, Exhibit
Conflict Minerals Disclosure and Report
A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.02 hereto and is publicly available at http://www.tevapharm.com/files/about/corporate_governance/governance_doc/Teva_Conflict_Minerals_Policy_Statement.pdf.
Item 2.01 Exhibits
Listed below is the following exhibit filed as part of this report:
Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.